GlaxoSmithKline Pharmaceuticals Limited conducted its Q1 FY 2027 Earnings Call on August 03, 2026, with management including Managing Director Bhushan Akshikar and CFO Rononjit Biswas.

The company reported strong financial performance for Q1 FY27 with sales of ₹924 crores, representing 15% year-on-year growth. EBITDA grew 17% year-on-year, with margins improving by 50 basis points. Profit After Tax reached ₹253 crores, growing 24% year-on-year with PAT margins expanding 200 basis points to 27.6%. Earnings per share for the quarter was ₹14.95.

The growth was attributed to three strategic priorities: growing top line relentlessly, accelerating pipeline launches of innovative assets from the global portfolio, and simplification through process improvements. The company noted a favorable base effect from last year's CMO disruptions that improved headline growth by 4-5%, making sustainable growth approximately 9-10% for the quarter.

Portfolio Performance

The innovation portfolio (IP-protected assets including oncology, respiratory drugs, and adult vaccines) contributed 7% of total revenues, nearly doubling from 4% last year and contributing approximately four percentage points of headline growth. Key products included:

  • Shingrix (adult vaccine): Grew 65% in the quarter, selling 45,000-50,000 doses quarterly, and has become an INR 100+ crores brand on MAT basis
  • Nucala and Trelegy Ellipta (respiratory): Patient uptake doubled from 50-60 patients monthly last year to 100-120 patients monthly in Q1 FY27
  • Oncology portfolio (Zejula for ovarian cancer and Jemperli for endometrial cancer): Impacted 260-270 patients in the quarter

The general medicines business, which represents the lion's share of the business, also grew double-digit. Pediatric vaccines maintained market leadership in the private segment.

Margin Drivers

Gross margins improved by approximately 150 basis points driven by pricing and product mix, despite some cost hardening from rupee depreciation. The company increased marketing investment with spend-to-sales ratio up about one percentage point, focused on product-specific investments behind new launches and core brands.

The PAT growth of 24% included a one-off dividend payout from 100% subsidiary Biddle Sawyer. Excluding this one-off, PAT growth would have been approximately 17%.

Upcoming Launches

Management confirmed several upcoming product launches:

  • Blenrep (Belantamab Mafodotin) for second-line refractory relapse multiple myeloma: Expected launch within next 2-3 months (Q2 or Q3 FY27)
  • Bepirovirsen (Hibsago) for chronic hepatitis B: Potential functional cure, expected launch in approximately 3 quarters
  • Arexvy: First adult vaccine for preventing respiratory syncytial virus, already has marketing authorization
  • Ojjaara: Future launch expected in next 18-24 months

Operational Metrics

The company has approximately 2,000 medical representatives with average productivity of ₹15-16 lakhs per rep, which improved 5-6% this quarter. The oncology team has 40-45 representatives who have achieved approximately ₹10 crores monthly revenue.

Market Context

The Indian pharmaceutical industry grew at 13.5% in Q1, with balanced growth between volume (2%), price, and new introductions. The growth was balanced between acute and chronic segments, with acute still contributing 60% of the overall pharma market. GSK's represented market grew better than the external market.

Investment Strategy

The company front-loaded investments in Q1 with nearly 3,800 HCP events and international speaker meets concentrated before the peak September quarter. Management expects investment ratios to moderate and return to historical trends in subsequent quarters, with S&A ratios normalizing and EBITDA margins expected to be around 34% for the year.

Manufacturing and Supply Chain

The company manufactures bulk of its general medicines business locally at its Nashik facility and through 20 contract manufacturers. Supply chain issues from previous CMO disruptions have been resolved, and the company has strengthened business continuity plans.

The company maintains its focus on portfolio transformation toward innovative, specialty-led business while protecting its established general medicines portfolio, with the goal of achieving INR 8,000 crores top line in 4-5 years.